Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 499

Results For "AI"

8746 News Found

Mandaviya addresses the G7 Health Ministerial Meeting on health innovation
Policy | May 16, 2023

Mandaviya addresses the G7 Health Ministerial Meeting on health innovation

The need is to focus on an enabling framework to bridge the digital divide across countries specifically amongst low-and-middle-income countries


Medico Remedies to foray into ointment manufacturing segment
News | May 15, 2023

Medico Remedies to foray into ointment manufacturing segment

The facility will have a capacity to manufacture upto 3 million tubes monthly


Advanced Enzyme Technologies posts Q4 FY23 consolidated PAT up at Rs. 32.12 Cr
News | May 15, 2023

Advanced Enzyme Technologies posts Q4 FY23 consolidated PAT up at Rs. 32.12 Cr

The company has reported total income of Rs. 149.78 crores during the period ended March 31, 2023


Briefs: Dr. Reddy's Laboratories and Max Healthcare Institute
News | May 15, 2023

Briefs: Dr. Reddy's Laboratories and Max Healthcare Institute

Dr. Reddy's Laboratories has been issued a Form 483 with four observations


Dr. Lal Path Labs posts Q4 FY23 consolidated PAT at Rs. 56.7 Cr
News | May 13, 2023

Dr. Lal Path Labs posts Q4 FY23 consolidated PAT at Rs. 56.7 Cr

Dr. Lal Path Labs has reported total income of Rs. 505.2 crores during the period ended March 31, 2023


Alembic Q4 FY23 consolidated PAT up at Rs. 48.25 Cr
News | May 13, 2023

Alembic Q4 FY23 consolidated PAT up at Rs. 48.25 Cr

Alembic has reported total income of Rs. 39.15 crores during the period ended March 31, 2023


Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
News | May 13, 2023

Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr

Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023


USFDA approves Astellas' Veozah’ for treatment of vasomotor symptoms due to menopause
Drug Approval | May 13, 2023

USFDA approves Astellas' Veozah’ for treatment of vasomotor symptoms due to menopause

VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause


Sanofi India to demerge healthcare businesses
News | May 12, 2023

Sanofi India to demerge healthcare businesses

This decision will accelerate growth for both its pharma & consumer healthcare businesses in India


Bliss GVS Pharma Q4 FY2023 consolidated PAT drops at Rs. 3.34 Cr
News | May 12, 2023

Bliss GVS Pharma Q4 FY2023 consolidated PAT drops at Rs. 3.34 Cr

The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023